Search
Search Results
-
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval
Aducanumab is the first FDA-approved amyloid-lowering immunotherapy for Alzheimer’s disease. There is little real-world data to guide management of...
-
Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid
BackgroundScreening data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) and Longitudinal Evaluation of Amyloid Risk and...
-
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy
Amyloid-related imaging abnormalities (ARIA) are adverse events reported in Alzheimer’s disease trials of anti-amyloid beta (Aβ) therapies. This...
-
Diagnosis, treatment, and follow-up of patients with cerebral amyloid angiopathy-related inflammation
PurposeCerebral amyloid angiopathy-related inflammation (CAA-ri) is a rare potentially reversible encephalopathy associated with an autoimmune...
-
Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography
BackgroundCerebral amyloid angiopathy (CAA) pathology is becoming increasingly important in Alzheimer’s disease (AD) because of its potential link to...
-
Clinicians’ Perspectives on How Disease Modifying Drugs for Alzheimer’s Disease Impact Specialty Care
Clinicians specialized in the diagnosis and management of persons living with early-stage Alzheimer’s disease need to enable access, for those...
-
Kausale Alzheimertherapie
Around 130,000 Austrians suffer from dementia, predominantly Alzheimer’s disease (AD), which is projected to double by 2050. An additional...
-
-
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
BackgroundAlzheimer’s disease (AD) is a worldwide public health problem and is difficult to cure. Drugs aimed at slowing the progression of the...
-
Amyloid-β related angiitis presenting as eosinophilic meningitis: a case report
BackgroundEosinophilic meningitis is uncommon and often attributed to infectious causes.
Case presentationWe describe a case of a 72-year-old man...
-
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi ® ) and aducanumab (Aduhelm ® )—have been approved in the USA for the treatment of...
-
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer’s Disease
BackgroundKHK6640 is a novel humanized anti-amyloid beta oligomer-specific antibody. Both KHK6640 and the mouse parent antibody E64 have demonstrated...
-
Vascular Considerations for Amyloid Immunotherapy
Purpose of ReviewAmyloid beta (Aβ) plaque accumulation is a hallmark pathology contributing to Alzheimer’s disease (AD) and is widely hypothesized to...
-
Aducanumab: an uprising hope with vague horizons
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Amyloid-beta (Aβ) deposition, is one of the processes involved in the...
-
Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer’s disease: a systematic review and meta-analysis
BackgroundStudies targeting amyloid-ß in patients with Alzheimer’s disease (AD) have conflicting results and early initiation of therapy may yield...
-
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Purpose of reviewDiscuss emerging anti-amyloid disease-modifying therapies for Alzheimer’s disease (AD) and outline how these therapies will change...
-
Cerebral Superficial Siderosis
Superficial siderosis (SS) of the central nervous system constitutes linear hemosiderin deposits in the leptomeninges and the superficial layers of...
